Immunomodulatory effects of sex hormones: Requirements for pregnancy and relevance in melanoma

Mayo Clinic Proceedings

Volumn 89, Issue 4, 2014, Pages 520-535

  Enninga, Elizabeth Ann L ^a   Holtan, Shernan G ^b   Creedon, Douglas J ^a   Dronca, Roxana S ^a   Nevala, Wendy K ^a   Ognjanovic, Simona ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHORIONIC GONADOTROPIN; CORTICOTROPIN RELEASING FACTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; IPILIMUMAB; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PLACENTAL GROWTH FACTOR; PROGESTERONE; PROLACTIN; RELAXIN; SEX HORMONE; TUMOR NECROSIS FACTOR ALPHA;

CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; FIRST TRIMESTER PREGNANCY; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; LYMPHOCYTOTOXICITY; MATERNAL IMMUNE RESPONSE; METASTATIC MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; OVERALL SURVIVAL; PREGNANCY; REVIEW; SEX DIFFERENCE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

ADULT; CHORIONIC GONADOTROPIN; ESTROGENS; FEMALE; GESTATIONAL AGE; GONADAL STEROID HORMONES; HUMANS; IMMUNE SYSTEM PROCESSES; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MELANOMA; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGESTERONE; PROGNOSIS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84898622960     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.01.006     Document Type: Review

References (190)

1. Krebs ET Jr, Krebs ET Sr, Beard HH. The Unitarian or Trophoblastic Thesis of Cancer. Med Rec. 1950;163(7):149-174.
2. BeardHH.Correlation of the unitarian or trophoblastic thesiswith the biological test of malignancy. Fed Proc. 1948;7(1, Pt 1):145.
3. Krebs ET Jr. Carcinogenesis; in the light of the trophoblastic or unitarian thesis of cancer. Int Rec Med Gen Pract Clin. 1951; 164(3):141-169; contd.
4. Ferretti C, Bruni L, Dangles-Marie V, Pecking AP, Bellet D. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2007;13(2): 121-141.
5. Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009;84(11):985-1000.
6. ParkDW, Yang KM. Hormonal regulation of uterine chemokines and immune cells. Clin Exp Reprod Med. 2011;38(4):179-185.
7. Belfiore A, Perks CM. Grand challenges in cancer endocrinology: endocrine related cancers, an expanding concept. Front Endocrinol (Lausanne). 2013;4:141.
8. Holtan SG, Mansfield AS, Creedon DJ, et al. An organ system based approach to prognosis in advanced melanoma. Front Biosci (Elite Ed). 2012;4:2823-2833.
9. Soeters PB, Grimble RF. The conditional role of inflammation in pregnancy and cancer. Clin Nutr. 2012;32(3): 460-465.
10. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP. CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med. 2009;7:102.
11. Leontovich AA, Dronca RS, Suman VJ, et al. Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed). 2012;4:958-975.
12. Dronca RS, Leontovich AA, Nevala WK, Markovic SN. Personalized therapy for metastatic melanoma: could timing be everything? Future Oncol. 2012;8(11):1401-1406.
13. Kirkpatrick HF, Robertson JD. Hormonal changes in pregnancy. Med Illus. 1953;7(7):553-555.
14. Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol. 2012;212:v-115.
15. Zouboulis CC, Chen WC, Thornton MJ, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res. 2007;39(2): 85-95.
16. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L- dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Mel Res. 2012;25(1):14-27.
17. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev. 2004;84(4):1155-1228.
18. Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma, III: hormonal and reproductive factors in women. Int J Cancer. 1988; 42(6):821-824.
19. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol. 2009;20(2):358-364.
20. Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control. 2008;19(5):437-442.
21. Stensheim H, Møller B, van Dijk T, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J ClinOncol. 2009;27(1):45-51.
22. Mansfield AS, Nevala WK, Dronca RS, Leontovich AA, Shuster L, Markovic SN. Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. Clin Exp Immunol. 2012;170(2):186-193.
23. Beddingfield FC III. The melanoma epidemic: res ipsa loquitur. Oncologist. 2003;8(5):459-465.
24. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622-3634.
25. Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg. 1998;175(6):437-444; discussion 444-445.
26. Shaw HM, Milton GW, Farago G, McCarthy WH. Endocrine influences on survival from malignant melanoma. Cancer. 1978;42(2):669-677.
27. Mervic L. Time course and pattern of metastasis of cutaneous melanoma differ between men and women. PLoS One. 2012; 7(3):e32955.
28. Ticconi C, Zicari A, Belmonte A, Realacci M, Rao ChV, Piccione E. Pregnancy-promoting actions of HCG in human myometrium and fetal membranes. Placenta. 2007;28(Suppl A):S137-S143.
29. Keay SD, Vatish M, Karteris E, Hillhouse EW, Randeva HS. The role of hCG in reproductive medicine. BJOG. 2004;111(11): 1218-1228.
30. Wan H, Versnel MA, Cheung WY, et al. Chorionic gonadotrophin can enhance innate immunity by stimulating macrophage function. J Leukoc Biol. 2007;82(4):926-933.
31. Schumacher A, Brachwitz N, Sohr S, et al. Human chorionic gonadotropin attracts regulatory T cells into the fetalmaternal interface during early human pregnancy. J Immunol. 2009;182(9):5488-5497.
32. Tsampalas M, Gridelet V, Berndt S, Foidart JM, Geenen V, Perrier d'Hauterive S. Human chorionic gonadotropin: a hormone with immunological and angiogenic properties. J Reprod Immunol. 2010;85(1):93-98.
33. Sherwin JR, Sharkey AM, Cameo P, et al. Identification of novel genes regulated by chorionic gonadotropin in baboon endometrium during the window of implantation. Endocrinology. 2007;148(2):618-626.
34. Kane N, Kelly R, Saunders PT, Critchley HO. Proliferation of uterine natural killer cells is induced by human chorionic gonadotropin and mediated via the mannose receptor. Endocrinology. 2009;150(6):2882-2888.
35. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol. 2006;6(8):584-594.
36. Vacca P, Moretta L, Moretta A, Mingari MC. Origin, phenotype and function of human natural killer cells in pregnancy. Trends Immunol. 2011;32(11):517-523.
37. Holtan SG, Creedon DJ, Thompson MA, Nevala WK, Markovic SN. Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol. 2011;2011:316314.
38. Koldehoff M, Katzorke T, Wisbrun NC, et al. Modulating impact of human chorionic gonadotropin hormone on the maturation and function of hematopoietic cells. J Leukoc Biol. 2011;90(5):1017-1026.
39. Reisinger K, Baal N, McKinnon T, Munstedt K, Zygmunt M. The gonadotropins: tissue-specific angiogenic factors? Mol Cell Endocrinol. 2007;269(1-2):65-80.
40. Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S. Vascular endothelial growth factorC facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J Immunol. 2009;182(7):4085-4092.
41. Berndt S, Perrier d'Hauterive S, Blacher S, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 2006;20(14):2630-2632.
42. Thaxton JE, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. Am J Reprod Immunol. 2010;63(6):482-491.
43. Brouillet S, Hoffmann P, Chauvet S, et al. Revisiting the role of hCG: new regulation of the angiogenic factor EG-VEGF and its receptors. Cell Mol Life Sci. 2012;69(9):1537-1550.
44. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A. Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. J Immunol. 2003;171(5):2305-2313.
45. Lei ZM, Rao CV, Ackerman DM, Day TG. The expression of human chorionic gonadotropin/human luteinizing hormone receptors in human gestational trophoblastic neoplasms. J Clin Endocrinol Metab. 1992;74(6):1236-1241.
46. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci. 2007;44(2):151-178.
47. Cole LA. hCG, the wonder of today's science. Reprod Biol Endocrinol. 2012;10:24.
48. Doi F, Chi DD, Charuworn BB, et al. Detection of betahuman chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int J Cancer. 1996;65(4): 454-459.
49. Ayala AR, Saad A, Vázquez X, Ramirez-Wiella G, Perches RD. Human chorionic gonadotropin immunoreactivity in serum of patients with malignant neoplasms. Am J Reprod Immunol. 1983;3(3):149-151.
50. Akhvlediani L, Nagervadze M, Dumbadze G. Detection of tolerance against human chorionic gonadotropin at malignant and benign tumors of female reproduction system. Georgian Med News. 2009;171:20-24.
51. Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer. 2000;82(9):1553-1556.
52. Zygmunt M, Herr F, Keller-Schoenwetter S, et al. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab. 2002;87(11): 5290-5296.
53. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol. 1993;151(9):4562-4573.
54. Szekeres-Bartho J, Halasz M, Palkovics T. Progesterone in pregnancy; receptor-ligand interaction and signaling pathways. J Reprod Immunol. 2009;83(1-2):60-64.
55. Szekeres-Bartho J, Barakonyi A, Polgar B, et al. The role of gamma/delta T cells in progesterone-mediated immunomodulation during pregnancy: a review. Am J Reprod Immunol. 1999;42(1):44-48.
56. Szekeres-Bartho J, Polgar B. PIBF: the double edged sword. Pregnancy and tumor. Am J Reprod Immunol. 2010;64(2):77-86.
57. Gadkar-Sable S, Shah C, Rosario G, Sachdeva G, Puri C. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci. 2005;10:2118-2130.
58. Tan H, Yi L, Rote NS, Hurd WW, Mesiano S. Progesterone receptor-A and-B have opposite effects on proinflammatory gene expression in human myometrial cells: implications for progesterone actions in human pregnancy and parturition. J Clin Endocrinol Metab. 2012;97(5):E719-E730.
59. Mesiano S, Chan EC, Fitter JT, Kwek K, Yeo G, Smith R. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. J Clin Endocrinol Metab. 2002;87(6):2924-2930.
60. Vrachnis N, Malamas FM, Sifakis S, Tsikouras P, Iliodromiti Z. Immune aspects and myometrial actions of progesterone and CRH in labor. Clin Dev Immunol. 2012; 2012:937618.
61. Ishida M, Choi JH, Hirabayashi K, et al. Reproductive phenotypes in mice with targeted disruption of the 20alpha-hydroxysteroid dehydrogenase gene. J Reprod Dev. 2007;53(3):499-508.
62. Arck PC, Rücke M, Rose M, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online. 2008;17(1):101-113.
63. Szekeres-Bartho J, Hadnagy J, Pacsa AS. The suppressive effect of progesterone on lymphocyte cytotoxicity: unique progesterone sensitivity of pregnancy lymphocytes. J Reprod Immunol. 1985;7(2):121-128.
64. Liang J, Sun L, Wang Q, Hou Y. Progesterone regulates mouse dendritic cells differentiation and maturation. Int Immunopharmacol. 2006;6(5):830-838.
65. De León-Nava MA, Nava K, Soldevila G, et al. Immune sexual dimorphism: effect of gonadal steroids on the expression of cytokines, sex steroid receptors, and lymphocyte proliferation. J Steroid Biochem Mol Biol. 2009;113(1-2):57-64.
66. Piccinni MP, Giudizi MG, Biagiotti R, et al. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol. 1995;155(1):128-133.
67. Canellada A, Blois S, Gentile T, Margni Idehu RA. In vitro modulation of protective antibody responses by estrogen, progesterone and interleukin-6. Am J Reprod Immunol. 2002; 48(5):334-343.
68. Slominski A, Gomez-Sanchez CE, Foecking MF, Wortsman J. Metabolism of progesterone to DOC, corticosterone and 18OHDOC in cultured human melanoma cells. FEBS Lett. 1999;455(3):364-366.
69. Slominski A, Ermak G, Mihm M. ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin. J Clin Endocrinol Metab. 1996;81(7):2746-2749.
70. Slominski A, Zjawiony J, Wortsman J, et al. A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur J Biochem. 2004;271(21):4178-4188.
71. Wiedemann C, Nägele U, Schramm G, Berking C. Inhibitory effects of progestogens on the estrogen stimulation of melanocytes in vitro. Contraception. 2009;80(3): 292-298.
72. Im S, Lee ES, Kim W, et al. Donor specific response of estrogen and progesterone on cultured human melanocytes. J Korean Med Sci. 2002;17(1):58-64.
73. Fang X, Zhang X, Zhou M, Li J. Effects of progesterone on the growth regulation in classical progesterone receptor-negative malignant melanoma cells. J Huazhong Univ Sci Technolog Med Sci. 2010;30(2):231-234.
74. Kozma N, Halasz M, Polgar B, et al. Progesterone-induced blocking factor activates STAT6 via binding to a novel IL-4 receptor. J Immunol. 2006;176(2):819-826.
75. Kanda N, Watanabe S. 17beta-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J Invest Dermatol. 2001;117(2):274-283.
76. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN, Melanoma Study Group of the Mayo Clinic Cancer Center. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009;15(6):1931-1939.
77. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001; 7(5):575-583.
78. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996; 271(30):17629-17634.
79. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood. 2003;102(4):1515-1524.
80. Bagley RG, Ren Y, Weber W, et al. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res. 2011;17(5):976-988.
81. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-475.
82. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell. 2002;1(1):99-108.
83. Loges S, Schmidt T, Carmeliet P. "Antimyeloangiogenic" therapy for cancer by inhibiting PlGF. Clin Cancer Res. 2009;15(11): 3648-3653.
84. Bryant-Greenwood GD, Yamamoto SY, Sadowsky DW, Gravett MG, Novy MJ. Relaxin stimulates interleukin-6 and interleukin-8 secretion from the extraplacental chorionic cytotrophoblast. Placenta. 2009;30(7):599-606.
85. Tashima LS, Mazoujian G, Bryant-Greenwood GD. Human relaxins in normal, benign and neoplastic breast tissue. J Mol Endocrinol. 1994;12(3):351-364.
86. Mazoujian G, Bryant-Greenwood GD. Relaxin in breast tissue. Lancet. 1990;335(8684):298-299.
87. Hansell DJ, Bryant-Greenwood GD, Greenwood FC. Expression of the human relaxin H1 gene in the decidua, trophoblast, and prostate. J Clin Endocrinol Metab. 1991;72(4):899-904.
88. Perkins AV, Wolfe CD, Eben F, Soothill P, Linton EA. Corticotrophin- releasing hormone-binding protein in human fetal plasma. J Endocrinol. 1995;146(3):395-401.
89. Grammatopoulos DK, Hillhouse EW. Role of corticotropinreleasing hormone in onset of labour. Lancet. 1999; 354(9189):1546-1549.
90. Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000;80(3):979-1020.
91. Slominski A, Zbytek B, Szczesniewski A, et al. CRH stimulation of corticosteroids production in melanocytes is mediated by ACTH. Am J Physiol Endocrinol Metab. 2005;288(4):E701-E706.
92. Yang Y, Park H, Yang Y, Kim TS, Bang SI, Cho D. Enhancement of cell migration by corticotropin-releasing hormone through ERK1/2 pathway in murine melanoma cell line, B16F10. Exp Dermatol. 2007;16(1):22-27.
93. Kim MH, Cho D, Kim HJ, et al. Investigation of the corticotropin- releasing hormone-proopiomelanocortin axis in various skin tumours. Br J Dermatol. 2006;155(5):910-915.
94. Slominski A, Zbytek B, Zmijewski M, et al. Corticotropin releasing hormone and the skin. Front Biosci. 2006;11: 2230-2248.
95. Slominski AT, Zmijewski MA, Zbytek B, Tobin DJ, Theoharides TC, Rivier J. Key role of CRF in the skin stress response system. Endocr Rev. 2013;34(6):827-884.
96. Carlson KW, Nawy SS, Wei ET, et al. Inhibition of mouse melanoma cell proliferation by corticotropin-releasing hormone and its analogs. Anticancer Res. 2001;21(2A):1173-1179.
97. Slominski A, Zbytek B, Pisarchik A, Slominski RM, Zmijewski MA, Wortsman J. CRH functions as a growth factor/cytokine in the skin. J Cell Physiol. 2006;206(3):780-791.
98. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995; 332(20):1351-1362.
99. Ilias I, Mastorakos G. The emerging role of peripheral corticotropin-releasing hormone (CRH). J Endocrinol Invest. 2003;26(4):364-371.
100. Ciereszko RE, Petroff BK, Ottobre AC, Guan Z, Stokes BT, Ottobre JS. Assessment of the mechanism by which prolactin stimulates progesterone production by early corpora lutea of pigs. J Endocrinol. 1998;159(2):201-209.
101. Herrera E, Muñoz C, López-Luna P, Ramos P. Carbohydratelipid interactions during gestation and their control by insulin. Braz J Med Biol Res. 1994;27(11):2499-2519.
102. Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res. 1997; 29(6):301-307.
103. Lellis-Santos C, Sakamoto LH, Bromati CR, et al. The regulation of Rasd1 expression by glucocorticoids and prolactin controls peripartum maternal insulin secretion. Endocrinology. 2012;153(8):3668-3678.
104. Voogt JL, Lee Y, Yang S, Arbogast L. Regulation of prolactin secretion during pregnancy and lactation. Prog Brain Res. 2001;133:173-185.
105. Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI. The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol. 2000;14(10):1536-1549.
106. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589-600.
107. Matera L, Contarini M, Bellone G, Forno B, Biglino A. Upmodulation of interferon-gamma mediates the enhancement of spontanous cytotoxicity in prolactin-activated natural killer cells. Immunology. 1999;98(3):386-392.
108. Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett. 2005;101(2):123-143.
109. Chavez-Rueda K, Hérnández J, Zenteno E, Leaños-Miranda A, Legorreta-Haquet MV, Blanco-Favela F. Identification of prolactin as a novel immunomodulator on the expression of co-stimulatory molecules and cytokine secretions on T and B human lymphocytes. Clin Immunol. 2005;116(2):182-191.
110. Yu-Lee LY. Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res. 2002;57:435-455.
111. Orbach H, Zandman-Goddard G, Amital H, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007;1109:385-400.
112. Majumder B, Biswas R, Chattopadhyay U. Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12. Int J Cancer. 2002;97(4): 493-500.
113. Sun R, Wei H, Zhang J, Li A, Zhang W, Tian Z. Recombinant human prolactin improves antitumor effects of murine natural killer cells in vitro and in vivo. Neuroimmunomodulation. 2002-2003;10(3):169-176.
114. Swaminathan G, Varghese B, Fuchs SY. Regulation of prolactin receptor levels and activity in breast cancer. J Mammary Gland Biol Neoplasia. 2008;13(1):81-91.
115. Asher JM, O'Leary KA, Rugowski DE, Arendt LM, Schuler LA. Prolactin promotes mammary pathogenesis independently from cyclin d1. Am J Pathol. 2012;181(1):294-302.
116. Chikanza IC. Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci. 1999;876:119-130.
117. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19(3):225-268.
118. Peverelli E, Mantovani G, Vitali E, et al. Filamin-A is essential for dopamine d2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab. 2012;97(3):967-977.
119. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724-763.
120. Richards SM, Murphy WJ. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol. 2000;109(1):56-62.
121. Tabruyn SP, Sabatel C, Nguyen NQ, et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation. Mol Endocrinol. 2007;21(6):1422-1429.
122. Nguyen NQ, Castermans K, Berndt S, et al. The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation. PLoS One. 2011;6(11):e27318.
123. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249-257.
124. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14(2): 1431-1437.
125. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colonyenhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32(11):3225-3234.
126. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748- 1758.
127. Ognjanovic S, Tashima LS, Bryant-Greenwood GD. The effects of pre-B-cell colony-enhancing factor on the human fetal membranes by microarray analysis. Am J Obstet Gynecol. 2003; 189(4):1187-1195.
128. Lappas M. Visfatin regulates the terminal processes of human labour and delivery via activation of the nuclear factor-kappaB pathway. Mol Cell Endocrinol. 2012;348(1):128-134.
129. Mazaki-Tovi S, Romero R, Vaisbuch E, et al. Maternal plasma visfatin in preterm labor. J Matern Fetal Neonatal Med. 2009; 22(8):693-704.
130. Maldi E, Travelli C, Caldarelli A, et al. Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions. Pigment Cell Melanoma Res. 2013;26(1): 144-146.
131. Bułdak RJ, Bułdak Ł, Polaniak R, et al. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol Rep. 2013;29(2): 771-778.
132. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest. 2004;113(9):1318-1327.
133. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol. 2003;176(3):293-304.
134. Cohen-Solal JF, Jeganathan V, Grimaldi CM, Peeva E, Diamond B. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol. 2006;305: 67-88.
135. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521-574.
136. Zang YC, Halder JB, Hong J, Rivera VM, Zhang JZ. Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol. 2002;124(1-2):106-114.
137. Phiel KL, Henderson RA, Adelman SJ, Elloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett. 2005; 97(1):107-113.
138. Holtan SG, Creedon DJ. Mother knows best: lessons from fetomaternal tolerance applied to cancer immunity. Front Biosci (Schol Ed). 2011;3:1533-1540.
139. Lee YL, Cheong AW, Chow WN, Lee KF, Yeung WS. Regulation of complement-3 protein expression in human and mouse oviducts. Mol Reprod Dev. 2009;76(3):301-308.
140. Shifren JL, Tseng JF, Zaloudek CJ, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Enndocrinol Metab. 1996;81(8):3112-3118.
141. Hildebrandt VA, Babischkin JS, Koos RD, Pepe GJ, Albrecht ED. Developmental regulation of vascular endothelial growth/permeability factor messenger ribonucleic acid levels in and vascularization of the villous placenta during baboon pregnancy. Endocrinology. 2001;142(5):2050-2057.
142. Schoenberg BS, Christine BW. Malignant melanoma associated with breast cancer. South Med J. 1980;73(11): 1493-1497.
143. Walker MJ, Beattie CW, Patel MK, Ronan SM, Das Gupta TK. Estrogen receptor in malignant melanoma. J Clin Oncol. 1987; 5(8):1256-1261.
144. Zen M, Ghirardello A, Iaccarino L, et al. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly. 2010;140(13-14):187-201.
145. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002;109(12):1625-1633.
146. Cutolo M, Sulli A, Craviotto C, et al. Modulation of cell growth and apoptosis by sex hormones in cultured monocytic THP-1 cells. Ann N Y Acad Sci. 2002;966:204-210.
147. Hughes GC, Clark EA. Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity. 2007;40(6):470-481.
148. Calippe B, Douin-Echinard V, Laffargue M, et al. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. J Immunol. 2008;180(12):7980-7988.
149. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol. 2003;38(1):13-22.
150. Evans MJ, MacLaughlin S, Marvin RD, Abdou NI. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. Clin Immunol Immunopathol. 1997;82(3):258-262.
151. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997; 138(3):863-870.
152. Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol. 2008;35(4):215-221.
153. Schmidt AN, Nanney LB, Boyd AS, King LE Jr, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol. 2006;15(12):971-980.
154. Scolyer RA, Judge MJ, Evans A, et al. Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Am J Surg Pathol. 2013;37(12):1797- 1814.
155. de Giorgi V, Mavilia C, Massi D, et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol. 2009;145(1):30-36.
156. Mor G, Sapi E, Abrahams VM, et al. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J Immunol. 2003;170(1):114-122.
157. Paharkova-Vatchkova V, Maldonado R, Kovats S. Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors. J Immunol. 2004;172(3):1426-1436.
158. Mao A, Paharkova-Vatchkova V, Hardy J, Miller MM, Kovats S. Estrogen selectively promotes the differentiation of dendritic cells with characteristics of Langerhans cells. J Immunol. 2005; 175(8):5146-5151.
159. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell. 2003;3(4):363-375.
160. Miller VM. Sex-based differences in vascular function. Women's Health (Lond Engl). 2010;6(5):737-752.
161. Raaz-Schrauder D, Klinghammer L, Baum C, et al. Association of systemic inflammation markers with the presence and extent of coronary artery calcification. Cytokine. 2012;57(2):251-257.
162. Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med. 2000;343(8):530-537.
163. Pennell LM, Galligan CL, Fish EN. Sex affects immunity. J Autoimmun. 2012;38(2-3):J282-J291.
164. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777-780.
165. Ostensen M, Villiger PM. Immunology of pregnancydpregnancy as a remission inducing agent in rheumatoid arthritis. Transpl Immunol. 2002;9(2-4):155-160.
166. Scotland RS, Stables MJ, Madalli S, Watson P, Gilroy DW. Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. Blood. 2011;118(22):5918-5927.
167. Marriott I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Res. 2006; 34(3):177-192.
168. Adrie C, Azoulay E, Francais A, et al. Influence of gender on the outcome of severe sepsis: a reappraisal. Chest. 2007; 132(6):1786-1793.
169. Hill JA, Polgar K, Anderson DJ. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA. 1995;273(24):1933-1936.
170. Moraru M, Carbone J, Alecsandru D, et al. Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells. Am J Reprod Immunol. 2012;68(1): 75-84.
171. Jin LP, Zhou YH, Wang MY, Zhu XY, Li DJ. Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings. J Reprod Immunol. 2005;65(2):133-146.
172. Fan W, Li SW, Liu XR. Influence of blockade of costimulation on Th1/Th2 cytokines shift in unexplained early recurrent spontaneous [in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006;37(5):773-775.
173. Li W, Li B, Fan W, et al. CTLA4Ig gene transfer alleviates abortion in mice by expanding CD4+CD25+ regulatory T cells and inducing indoleamine 2,3-dioxygenase. J Reprod Immunol. 2009;80(1-2):1-11.
174. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008;13(Suppl 4):16-25.
175. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
176. Trinh VA, Hagen B. Ipilimumab for advanced melanoma: a pharmacologic perspective. J Oncol Pharm Pract. 2013;19(3): 195-201.
177. Dulos J, Carven GJ, van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169-178.
178. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
179. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2): 122-133.
180. Sugiyama D, Nishikawa H, Maeda Y, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A. 2013;110(44):17945-17950.
181. Ma J, Han H, Liu D, et al. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy. PLoS One. 2013; 8(8):e73261.
182. Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology. 2013;2(5):e24436.
183. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-145.
184. Slominski A, Zbytek B, Slominski R. Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Intl J Cancer. 2009;124(6):1470-1477.
185. Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013;137:107-123.
186. Mordoh J, Tapia IJ, Barrio MM. A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment. BMC Cancer. 2013;13:132.
187. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562-567.
188. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008;105(27):9331-9336.
189. Lin PY, Sun L, Thibodeaux SR, et al. B7-H1-dependent sexrelated differences in tumor immunity and immunotherapy responses. J Immunol. 2010;185(5):2747-2753.
190. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443- 2454.